You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells

 

Online download statistics by month:

Online download statistics by month: June 2023 to September 2025

AbstractFullPdf
Jun 2023549552135
Jul 202321321349
Aug 202321321540
Sep 202311311324
Oct 202310210245
Nov 202313513543
Dec 20239910064
Jan 2024868755
Feb 2024828236
Mar 202412612689
Apr 2024929355
May 202410010040
Jun 202411411442
Jul 202417017258
Aug 2024838431
Sep 202496961244
Oct 202410110352
Nov 2024848634
Dec 202414814955
Jan 2025939342
Feb 202515515554
Mar 202515515545
Apr 202513213255
May 202513313652
Jun 2025575729
Jul 2025110
Sep 2025110
Total343334522468